The 31st International Conference on Antiviral Research (ICAR) was held in Porto, Portugal from June 11-15, 2018. In this report, volunteer rapporteurs provide their summaries of scientific presentations, hoping to effectively convey the speakers' goals and the results and conclusions of their talks. This report provides an overview of the invited keynote and award lectures and highlights of short oral presentations, from the perspective of experts in antiviral research. Of note, a session on human cytomegalovirus included an update on the introduction to the clinic of letermovir for the prevention of CMV infection and disease. The 31st ICAR successfully promoted new discoveries in antiviral research and drug development. The 32nd ICAR will be held in Baltimore, Maryland, USA, May 6-10, 2019.

AIDS Research Institute Irsicaixa Hospital Germans Trias i Pujol Universitat Autónoma de Barcelona Badalona Spain

Cancer Research Centre of Lyon INSERM U1052 UMR_5286 CNRS University of Lyon Lyon France

Chevy Chase MD USA

Drake University College of Pharmacy and Health Sciences Des Moines IA USA

Evotec Sudbury MA USA

Institute for Antiviral Research Utah State University Logan UT USA

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Flemingovo nam 2 CZ 16610 Prague 6 Czech Republic

KU Leuven Rega Institute for Medical Research Laboratory of Virology and Chemotherapy B 3000 Leuven Belgium

SUNY Upstate Medical University Syracuse NY USA

Virology Division Dept of Infectious Diseases and Immunology Faculty of Veterinary Medicine Utrecht University Utrecht The Netherlands

Zobrazit více v PubMed

Andrei G., Carter K., Janeba Z., Sampath A., Schang L.M., Tarbet E.B., Vere Hodge R.A., Bray M., Este J.A. Highlights of the 30th international conference on antiviral research. Antivir. Res. 2017;145:184–196. PubMed PMC

Archin N.M., Liberty A.L., Kashuba A.D., Choudhary S.K., Kuruc J.D., Crooks A.M., Parker D.C., Anderson E.M., Kearney M.F., Strain M.C., Richman D.D., Hudgens M.G., Bosch R.J., Coffin J.M., Eron J.J., Hazuda D.J., Margolis D.M. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487:482–485. PubMed PMC

Badia R., Pujantell M., Riveira-Muñoz E., Puig T., Torres-Torronteras J., Martí R., Clotet B., Ampudia R.M., Vives-Pi M., Esté J.A., Ballana E. The G1/S specific cyclin D2 is a regulator of HIV-1 restriction in non-proliferating cells. PLoS Pathog. 2016;12 1005810.1001371/journal.ppat.1005829. PubMed PMC

Badia R., Pujantell M., Torres-Torronteras J., Menendez-Arias L., Marti R., Ruzo A., Pauls E., Clotet B., Ballana E., Este J.A., Riveira-Munoz E. SAMHD1 is active in cycling cells permissive to HIV-1 infection. Antivir. Res. 2017;142:123–135. PubMed

Ballana E., Este J.A. SAMHD1: at the crossroads of cell proliferation, immune responses, and virus restriction. Trends Microbiol. 2015;23:680–692. PubMed

Berke J.M., Dehertogh P., Vergauwen K., Van Damme E., Mostmans W., Vandyck K., Pauwels F. Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus. Antimicrob. Agents Chemother. 2017;61 pii: e00560-00517. PubMed PMC

Carette J.E., Raaben M., Wong A.C., Herbert A.S., Obernosterer G., Mulherkar N., Kuehne A.I., Kranzusch P.J., Griffin A.M., Ruthel G., Dal Cin P., Dye J.M., Whelan S.P., Chandran K., Brummelkamp T.R. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature. 2011;477:340–343. PubMed PMC

Chang J., Warren T.K., Zhao X., Gill T., Guo F., Wang L., Comunale M.A., Du Y., Alonzi D.S., Yu W., Ye H., Liu F., Guo J.T., Mehta A., Cuconati A., Butters T.D., Bavari S., Xu X., Block T.M. Small molecule inhibitors of ER alpha-glucosidases are active against multiple hemorrhagic fever viruses. Antivir. Res. 2013;98:432–440. PubMed PMC

Cromm P.M., Crews C.M. Targeted protein degradation: from chemical biology to drug discovery. Cell Chem. Biol. 2017;24:1181–1190. PubMed PMC

Decorsière A., Mueller H., van Breugel P.C., Abdul F., Gerossier L., Beran R.K., Livingston C.M., Niu C., Fletcher S.P., Hantz O., Strubin M. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature. 2016;531:386. PubMed

Dion S., Bourgine M., Godon O., Levillayer F., Michel M.L. Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules. J. Virol. 2013;87:5554–5563. PubMed PMC

Dudas G., Carvalho L.M., Bedford T., Tatem A.J., Baele G., Faria N.R., Park D.J., Ladner J.T., Arias A., Asogun D., Bielejec F., Caddy S.L., Cotten M., D'Ambrozio J., Dellicour S., Di Caro A., Diclaro J.W., Duraffour S., Elmore M.J., Fakoli L.S., Faye O., Gilbert M.L., Gevao S.M., Gire S., Gladden-Young A., Gnirke A., Goba A., Grant D.S., Haagmans B.L., Hiscox J.A., Jah U., Kugelman J.R., Liu D., Lu J., Malboeuf C.M., Mate S., Matthews D.A., Matranga C.B., Meredith L.W., Qu J., Quick J., Pas S.D., Phan M.V.T., Pollakis G., Reusken C.B., Sanchez-Lockhart M., Schaffner S.F., Schieffelin J.S., Sealfon R.S., Simon-Loriere E., Smits S.L., Stoecker K., Thorne L., Tobin E.A., Vandi M.A., Watson S.J., West K., Whitmer S., Wiley M.R., Winnicki S.M., Wohl S., Wolfel R., Yozwiak N.L., Andersen K.G., Blyden S.O., Bolay F., Carroll M.W., Dahn B., Diallo B., Formenty P., Fraser C., Gao G.F., Garry R.F., Goodfellow I., Gunther S., Happi C.T., Holmes E.C., Kargbo B., Keita S., Kellam P., Koopmans M.P.G., Kuhn J.H., Loman N.J., Magassouba N., Naidoo D., Nichol S.T., Nyenswah T., Palacios G., Pybus O.G., Sabeti P.C., Sall A., Stroher U., Wurie I., Suchard M.A., Lemey P., Rambaut A. Virus genomes reveal factors that spread and sustained the Ebola epidemic. Nature. 2017;544:309–315. PubMed PMC

EASL EASL recommendations on treatment of hepatitis C 2018. J. Hepatol. 2018;69:461–511. PubMed

Edwards T.C., Lomonosova E., Patel J.A., Li Q., Villa J.A., Gupta A.K., Morrison L.A., Bailly F., Cotelle P., Giannakopoulou E., Zoidis G., Tavis J.E. Inhibition of hepatitis B virus replication by N-hydroxyisoquinolinediones and related polyoxygenated heterocycles. Antivir. Res. 2017;143:205–217. PubMed PMC

Faria N.R., Rambaut A., Suchard M.A., Baele G., Bedford T., Ward M.J., Tatem A.J., Sousa J.D., Arinaminpathy N., Pepin J., Posada D., Peeters M., Pybus O.G., Lemey P. HIV epidemiology. The early spread and epidemic ignition of HIV-1 in human populations. Science. 2014;346:56–61. PubMed PMC

Ferir G., Petrova M.I., Andrei G., Huskens D., Hoorelbeke B., Snoeck R., Vanderleyden J., Balzarini J., Bartoschek S., Bronstrup M., Sussmuth R.D., Schols D. The lantibiotic peptide labyrinthopeptin A1 demonstrates broad anti-HIV and anti-HSV activity with potential for microbicidal applications. PLoS One. 2013;8 PubMed PMC

Gollnest T., de Oliveira T.D., Schols D., Balzarini J., Meier C. Lipophilic prodrugs of nucleoside triphosphates as biochemical probes and potential antivirals. Nat. Commun. 2015;6:8716. PubMed PMC

Gollnest T., Dinis de Oliveira T., Rath A., Hauber I., Schols D., Balzarini J., Meier C. Membrane-permeable triphosphate prodrugs of nucleoside analogues. Angew Chem. Int. Ed. Engl. 2016;55:5255–5258. PubMed

Guo F., Wu S., Julander J., Ma J., Zhang X., Kulp J., Cuconati A., Block T.M., Du Y., Guo J.T., Chang J. A novel benzodiazepine compound inhibits yellow fever virus infection by specifically targeting NS4B protein. J. Virol. 2016;90:10774–10788. PubMed PMC

Huang L.R., Wohlleber D., Reisinger F., Jenne C.N., Cheng R.L., Abdullah Z., Schildberg F.A., Odenthal M., Dienes H.P., van Rooijen N., Schmitt E., Garbi N., Croft M., Kurts C., Kubes P., Protzer U., Heikenwalder M., Knolle P.A. Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection. Nat. Immunol. 2013;14:574–583. PubMed

Ivanova L., Buch A., Dohner K., Pohlmann A., Binz A., Prank U., Sandbaumhuter M., Bauerfeind R., Sodeik B. Conserved tryptophan motifs in the large tegument protein pUL36 are required for efficient secondary envelopment of herpes simplex virus capsids. J. Virol. 2016;90:5368–5383. PubMed PMC

Komazin-Meredith G., Cardinale S.C., Comeau K., Magalhaes K.J., Hartline C.B., Williams J.D., Opperman T.J., Prichard M.N., Bowlin T.L. TAOK3 phosphorylates the methylenecyclopropane nucleoside MBX 2168 to its monophosphate. Antivir. Res. 2015;119:23–27. PubMed PMC

Lahaye X., Satoh T., Gentili M., Cerboni S., Conrad C., Hurbain I., El Marjou A., Lacabaratz C., Lelievre J.D., Manel N. The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells. Immunity. 2013;39:1132–1142. PubMed

Lambert D.M., Barney S., Lambert A.L., Guthrie K., Medinas R., Davis D.E., Bucy T., Erickson J., Merutka G., Petteway S.R., Jr. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc. Natl. Acad. Sci. U. S. A. 1996;93:2186–2191. PubMed PMC

Lan H., Tang Z., Jin H., Sun Y. Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells. Sci. Rep. 2016;6:24218. PubMed PMC

Liljeroos L., Krzyzaniak M.A., Helenius A., Butcher S.J. Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc. Natl. Acad. Sci. U. S. A. 2013;110:11133–11138. PubMed PMC

Lomonosova E., Daw J., Garimallaprabhakaran A.K., Agyemang N.B., Ashani Y., Murelli R.P., Tavis J.E. Efficacy and cytotoxicity in cell culture of novel alpha-hydroxytropolone inhibitors of hepatitis B virus ribonuclease H. Antivir. Res. 2017;144:164–172. PubMed PMC

Ma J., Wu S., Zhang X., Guo F., Yang K., Guo J., Su Q., Lu H., Lam P., Li Y., Yan Z., Kinney W., Guo J.T., Block T.M., Chang J., Du Y. Ester prodrugs of IHVR-19029 with enhanced oral exposure and prevention of gastrointestinal glucosidase interaction. ACS Med. Chem. Lett. 2017;8:157–162. PubMed PMC

Martinez-Gualda B., Sun L., Rivero-Buceta E., Flores A., Quesada E., Balzarini J., Noppen S., Liekens S., Schols D., Neyts J., Leyssen P., Mirabelli C., Camarasa M.J., San-Felix A. Structure-activity relationship studies on a Trp dendrimer with dual activities against HIV and enterovirus A71. Modifications on the amino acid. Antivir. Res. 2017;139:32–40. PubMed

Marty F.M., Ljungman P., Chemaly R.F., Maertens J., Dadwal S.S., Duarte R.F., Haider S., Ullmann A.J., Katayama Y., Brown J., Mullane K.M., Boeckh M., Blumberg E.A., Einsele H., Snydman D.R., Kanda Y., DiNubile M.J., Teal V.L., Wan H., Murata Y., Kartsonis N.A., Leavitt R.Y., Badshah C. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N. Engl. J. Med. 2017;377:2433–2444. PubMed

Mehellou Y., Rattan H.S., Balzarini J. The ProTide prodrug technology: from the concept to the clinic. J. Med. Chem. 2018;61:2211–2226. PubMed PMC

Meier C. Nucleoside diphosphate and triphosphate prodrugs - an unsolvable task? Antivir. Chem. Chemother. 2017;25:69–82. PubMed PMC

Meier C., Balzarini J. Application of the cycloSal-prodrug approach for improving the biological potential of phosphorylated biomolecules. Antivir. Res. 2006;71:282–292. PubMed

Miller E.H., Obernosterer G., Raaben M., Herbert A.S., Deffieu M.S., Krishnan A., Ndungo E., Sandesara R.G., Carette J.E., Kuehne A.I., Ruthel G., Pfeffer S.R., Dye J.M., Whelan S.P., Brummelkamp T.R., Chandran K. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J. 2012;31:1947–1960. PubMed PMC

Oiknine-Djian E., Weisblum Y., Panet A., Wong H.N., Haynes R.K., Wolf D.G. The artemisinin derivative artemisone is a potent inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 2018;62:13. e00288-00218. PubMed PMC

Pauls E., Badia R., Torres-Torronteras J., Ruiz A., Permanyer M., Riveira-Muñoz E., Clotet B., Marti R., Ballana E., Esté J.A. Palbociclib, a selective inhibitor of cyclin-dependent kinase4/6, blocks HIV-1 reverse transcription through the control of sterile [alpha] motif and HD domain-containing protein-1 activity. AIDS. 2014;28:2213–2222. PubMed

Pujantell M., Franco S., Galván-Femenía I., Badia R., Castellví M., Garcia-Vidal E., Clotet B., de Cid R., Tural C., Martínez M.A., Riveira-Muñoz E., Esté J.A., Ballana E. ADAR1 affects HCV infection by modulating innate immune response. Antivir. Res. 2018;156:116–127. PubMed

Pujantell M., Riveira-Muñoz E., Badia R., Castellví M., Garcia-Vidal E., Sirera G., Puig T., Ramirez C., Clotet B., Esté J.A., Ballana E. RNA editing by ADAR1 regulates innate and antiviral immune functions in primary macrophages. Sci. Rep. 2017;7:13339. PubMed PMC

Scaturro P., Cortese M., Chatel-Chaix L., Fischl W., Bartenschlager R. Dengue virus non-structural protein 1 modulates infectious particle production via interaction with the structural proteins. PLoS Pathog. 2015;11 PubMed PMC

Shapira M.Y., Resnick I.B., Chou S., Neumann A.U., Lurain N.S., Stamminger T., Caplan O., Saleh N., Efferth T., Marschall M., Wolf D.G. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin. Infect. Dis. 2008;46:1455–1457. PubMed

Slusarczyk M., Serpi M., Pertusati F. Phosphoramidates and phosphonamidates (ProTides) with antiviral activity. Antivir. Chem. Chemother. 2018;26 2040206618775243. PubMed PMC

Staring J., van den Hengel L.G., Raaben M., Blomen V.A., Carette J.E., Brummelkamp T.R. KREMEN1 is a host entry receptor for a major group of enteroviruses. Cell Host Microbe. 2018;23:636–643. e635. PubMed

Staring J., von Castelmur E., Blomen V.A., van den Hengel L.G., Brockmann M., Baggen J., Thibaut H.J., Nieuwenhuis J., Janssen H., van Kuppeveld F.J., Perrakis A., Carette J.E., Brummelkamp T.R. PLA2G16 represents a switch between entry and clearance of Picornaviridae. Nature. 2017;541:412–416. PubMed

Suchard M.A., Lemey P., Baele G., Ayres D.L., Drummond A.J., Rambaut A. Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10. Virus Evol. 2018;4:vey016. PubMed PMC

Tan X., Chu C.K., Boudinot F.D. Development and optimization of anti-HIV nucleoside analogs and prodrugs: a review of their cellular pharmacology, structure-activity relationships and pharmacokinetics. Adv. Drug Deliv. Rev. 1999;39:117–151. PubMed

Vere Hodge R.A. vol. 100. 2013. pp. 276–285. (Meeting Report: 26th International Conference on Antiviral Research). Antiviral Research. PubMed PMC

Vere Hodge R.A. vol. 111. 2014. pp. 143–153. (Meeting Report: 27th International Conference on Antiviral Research, in Raleigh, NC, USA). Antiviral Research. PubMed PMC

Vere Hodge R.A. vol. 123. 2015. pp. 172–187. (Meeting Report: 28th International Conference on Antiviral Research in Rome, Italy). Antiviral Research. PubMed PMC

Vere Hodge R.A. vol. 137. 2017. pp. 23–40. (Meeting Report: 29th International Conference on Antiviral Research in La Jolla, CA, USA). Antiviral Research. PubMed PMC

Vu D.M., Mutai N., Heath C.J., Vulule J.M., Mutuku F.M., Ndenga B.A., LaBeaud A.D. Unrecognized dengue virus infections in children, Western Kenya, 2014-2015. Emerg. Infect. Dis. 2017;23:1915–1917. PubMed PMC

Wang J., Bardelli M., Espinosa D.A., Pedotti M., Ng T.S., Bianchi S., Simonelli L., Lim E.X.Y., Foglierini M., Zatta F., Jaconi S., Beltramello M., Cameroni E., Fibriansah G., Shi J., Barca T., Pagani I., Rubio A., Broccoli V., Vicenzi E., Graham V., Pullan S., Dowall S., Hewson R., Jurt S., Zerbe O., Stettler K., Lanzavecchia A., Sallusto F., Cavalli A., Harris E., Lok S.M., Varani L., Corti D. A human Bi-specific antibody against Zika virus with high therapeutic potential. Cell. 2017;171:229–241 e215. PubMed PMC

Weinschenk L., Schols D., Balzarini J., Meier C. Nucleoside diphosphate prodrugs: nonsymmetric DiPPro-nucleotides. J. Med. Chem. 2015;58:6114–6130. PubMed

Worobey M., Watts T.D., McKay R.A., Suchard M.A., Granade T., Teuwen D.E., Koblin B.A., Heneine W., Lemey P., Jaffe H.W. 1970s and 'Patient 0' HIV-1 genomes illuminate early HIV/AIDS history in North America. Nature. 2016;539:98–101. PubMed PMC

Wu G., Swanson M., Talla A., Graham D., Strizki J., Gorman D., Barnard R.J., Blair W., Sogaard O.S., Tolstrup M., Ostergaard L., Rasmussen T.A., Sekaly R.P., Archin N.M., Margolis D.M., Hazuda D.J., Howell B.J. HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. JCI Insight. 2017;2 doi: 10.1172/jci.insight.92901. PubMed DOI PMC

Meeting report of the 37th International Conference on Antiviral Research in Gold Coast, Australia, May 20-24, 2024, organized by the International Society for Antiviral Research

Meeting report: 36th International Conference on Antiviral Research in Lyon, France - March 13-17, 2023

Meeting report: 32nd International Conference on Antiviral Research